Rather than simply reading radiological scans, Ibex Medical Analytics is employing its artificial intelligence (AI)-powered cancer detection solutions to assist pathologists in the lab. Ibex’s Galen Platform is a clinical-grade, multi-tissue platform that helps pathologists detect a variety of cancers and grade their malignancies.  Ibex states that the platform can also “detect more than a hundred other clinically relevant diagnostic features in multiple tissue types.” Ibex leverages data extracted from millions of pathology slides along with AI and machine learning to perform its platform’s diagnostic functions.

Ibex reports that its breast cancer diagnostic tool, Galen Breast, delivered clinical grade accuracy in diagnosing multiple breast cancer types in a recent multi-site clinical study conducted at Institut Curie in France and Maccabi Healthcare Services in Israel. The study compared the performance of pathologists using Ibex AI against pathologists using traditional microscopes to diagnose multiple types of breast cancer. The study results showed the Galen Breast tool could detect various forms of breast cancer at a level of accuracy on par with trained pathologists. According to an Ibex press release, Galen Breast technology has shown the ability to detect both invasive and in-situ cancers in breast biopsies, distinguish between multiple sub-types of cancer (e.g., lobular versus ductal carcinoma), grade cancer severity in situ, and identify rare tumors. The Galen Platform additionally offers AI solutions for the detection of prostate and gastric cancers, which Ibex states also deliver clinical grade accuracy.

More recently, the company announced the launch of its latest Galen Platform version, Galen 3.0.  Ibex reports that Galen 3.0 provides expanded detection capabilities and a broader set of features to support pathologists in diagnoosing breat, prostrate, and gastric cancers.